Crossmark

Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells

Crossref DOI link: https://doi.org/10.1186/s40425-019-0558-4

Published Online: 2019-03-12

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Johanna, Inez

Straetemans, Trudy

Heijhuurs, Sabine

Aarts-Riemens, Tineke

Norell, Håkan

Bongiovanni, Laura

de Bruin, Alain

Sebestyen, Zsolt

Kuball, Jürgen
Funding

Funding for this research was provided by:

ZonMw (43400003, 917.11.337)

Universiteit Utrecht (2013-6426, 2014-6790, 2015-7601, 2018-11393)

Gadeta
License Information

Text and Data Mining valid from 2019-03-12
More Information

Article History

Received: 17 August 2018

Accepted: 4 March 2019

First Online: 12 March 2019

Ethics approval and consent to participate

: In vivo experiments were conducted according to Institutional Guidelines under acquired permission from the local Ethical Committee and per current Dutch laws on Animal Experimentation.

: Not applicable.

: JK received funding by Gadeta. JK and ZS are inventors on different patents with γδTCR sequences, recognition mechanism and isolation strategies. JK is CSO and shareholder of Gadeta.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below